Article

Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

Author(s):

OT Staff Reports

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
Avant Technologies and Ainnova Tech partner to advance retinal camera with AI-driven diagnostic platform
November 22nd 2024

Avant Technologies and Ainnova Tech partner to advance retinal camera with AI-driven diagnostic platform

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

AlloVir and Kalaris Therapeutics announce all-stock merger to focus on retinal diseases
November 22nd 2024

AlloVir and Kalaris Therapeutics announce all-stock merger to focus on retinal diseases

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
November 19th 2024

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy

Study examines the use of AI–based detection of diabetic retinopathy in the US
November 13th 2024

Study examines the use of AI–based detection of diabetic retinopathy in the US

© 2024 MJH Life Sciences

All rights reserved.